UY31470A1 - Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c - Google Patents
Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis cInfo
- Publication number
- UY31470A1 UY31470A1 UY31470A UY31470A UY31470A1 UY 31470 A1 UY31470 A1 UY 31470A1 UY 31470 A UY31470 A UY 31470A UY 31470 A UY31470 A UY 31470A UY 31470 A1 UY31470 A1 UY 31470A1
- Authority
- UY
- Uruguay
- Prior art keywords
- hepatitis
- virus
- compounds
- inhibitors
- compounds containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
Abstract
Compuestos de formula I y II o sales, ésteres, o prodrogas aceptables para uso farmacéutico de los mismos: que inhiben la actividad serina proteasa, en particular la actividad proteasa NS3-NS4A del virus de la hepatitis C (VHC). Consecuentemente, los compuestos de la presente invencion interfieren con el ciclo de vida del virus de la hepatitis C siendo utiles también como agentes antivirales. La invencion se relaciona además con composiciones farmacéuticas comprendiendo los compuestos antes mencionados para administrar a un sujeto que sufre de infeccion por VHC
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98795807P | 2007-11-14 | 2007-11-14 | |
US2545808P | 2008-02-01 | 2008-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31470A1 true UY31470A1 (es) | 2009-07-17 |
Family
ID=40639146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31470A UY31470A1 (es) | 2007-11-14 | 2008-11-14 | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c |
Country Status (26)
Country | Link |
---|---|
US (2) | US8324155B2 (es) |
EP (1) | EP2219453B1 (es) |
JP (1) | JP5479354B2 (es) |
KR (1) | KR20100098527A (es) |
CN (1) | CN101909446A (es) |
AR (1) | AR069464A1 (es) |
AU (1) | AU2008322537A1 (es) |
BR (1) | BRPI0820085A2 (es) |
CA (1) | CA2705807A1 (es) |
CL (1) | CL2008003384A1 (es) |
CO (1) | CO6280441A2 (es) |
CR (1) | CR11499A (es) |
DO (1) | DOP2010000143A (es) |
EC (1) | ECSP10010254A (es) |
ES (1) | ES2476257T3 (es) |
HK (1) | HK1146693A1 (es) |
IL (1) | IL205611A0 (es) |
MX (1) | MX2010005262A (es) |
MY (1) | MY155851A (es) |
PE (2) | PE20140189A1 (es) |
RU (1) | RU2493160C2 (es) |
TW (1) | TWI431011B (es) |
UA (1) | UA102677C2 (es) |
UY (1) | UY31470A1 (es) |
WO (1) | WO2009064975A1 (es) |
ZA (1) | ZA201003363B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
KR20080036598A (ko) | 2005-08-01 | 2008-04-28 | 머크 앤드 캄파니 인코포레이티드 | Hcv ns3 프로테아제 억제제로서의 마크로사이클릭펩티드 |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
WO2008051514A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
CA2667031C (en) | 2006-10-27 | 2013-01-22 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2007335962B2 (en) | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2178885A1 (en) | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
MX2010006518A (es) | 2007-12-14 | 2010-08-10 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. |
WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
CN102036966A (zh) | 2008-01-24 | 2011-04-27 | 益安药业 | 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽 |
CA2720850A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
WO2009134987A1 (en) * | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
PL2310095T3 (pl) | 2008-07-22 | 2013-03-29 | Msd Italia Srl | Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV |
EP2429568B1 (en) | 2009-05-13 | 2016-08-17 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
AU2011209051B2 (en) | 2010-01-27 | 2015-01-15 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
WO2011127350A1 (en) * | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
PE20140015A1 (es) * | 2010-09-21 | 2014-02-16 | Enanta Pharm Inc | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
NZ724616A (en) * | 2012-06-08 | 2018-06-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
SG11201408047XA (en) | 2012-06-08 | 2015-01-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
EA201691031A1 (ru) | 2013-12-23 | 2017-01-30 | Джилид Сайэнс, Инк. | Синтез макроциклического трипептида, ингибирующего hcv ns3 |
EP3087086B1 (en) * | 2013-12-23 | 2018-11-07 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
CN107074876B (zh) * | 2016-04-08 | 2019-12-20 | 上海长森药业有限公司 | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 |
CN107266529A (zh) * | 2016-04-08 | 2017-10-20 | 上海长森药业有限公司 | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 |
RU2650610C1 (ru) * | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR029903A1 (es) | 2000-04-05 | 2003-07-23 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
PA8603801A1 (es) * | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
JP5249028B2 (ja) * | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
KR20080036598A (ko) * | 2005-08-01 | 2008-04-28 | 머크 앤드 캄파니 인코포레이티드 | Hcv ns3 프로테아제 억제제로서의 마크로사이클릭펩티드 |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
UY30437A1 (es) * | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
CA2667031C (en) * | 2006-10-27 | 2013-01-22 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8377872B2 (en) * | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
WO2008134397A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
US8383583B2 (en) * | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
WO2009064955A1 (en) * | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
WO2009076173A2 (en) * | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Fluorinated tripeptide hcv serine protease inhibitors |
CN101932242A (zh) * | 2007-12-05 | 2010-12-29 | 益安药业 | 喹喔啉基衍生物 |
MX2010006518A (es) * | 2007-12-14 | 2010-08-10 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. |
WO2009079353A1 (en) * | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
US8283309B2 (en) * | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
-
2008
- 2008-11-13 CL CL2008003384A patent/CL2008003384A1/es unknown
- 2008-11-14 PE PE2013001102A patent/PE20140189A1/es not_active Application Discontinuation
- 2008-11-14 MY MYPI2010002236A patent/MY155851A/en unknown
- 2008-11-14 UA UAA201007220A patent/UA102677C2/uk unknown
- 2008-11-14 UY UY31470A patent/UY31470A1/es not_active Application Discontinuation
- 2008-11-14 CA CA2705807A patent/CA2705807A1/en not_active Abandoned
- 2008-11-14 EP EP08850226.5A patent/EP2219453B1/en not_active Not-in-force
- 2008-11-14 CN CN2008801250191A patent/CN101909446A/zh active Pending
- 2008-11-14 RU RU2010123928/04A patent/RU2493160C2/ru not_active IP Right Cessation
- 2008-11-14 PE PE2008001930A patent/PE20091212A1/es not_active Application Discontinuation
- 2008-11-14 AR ARP080104983A patent/AR069464A1/es unknown
- 2008-11-14 WO PCT/US2008/083541 patent/WO2009064975A1/en active Application Filing
- 2008-11-14 BR BRPI0820085A patent/BRPI0820085A2/pt not_active IP Right Cessation
- 2008-11-14 US US12/271,144 patent/US8324155B2/en not_active Expired - Fee Related
- 2008-11-14 KR KR1020107012702A patent/KR20100098527A/ko not_active Application Discontinuation
- 2008-11-14 MX MX2010005262A patent/MX2010005262A/es active IP Right Grant
- 2008-11-14 TW TW097144049A patent/TWI431011B/zh active
- 2008-11-14 JP JP2010534203A patent/JP5479354B2/ja active Active
- 2008-11-14 AU AU2008322537A patent/AU2008322537A1/en not_active Abandoned
- 2008-11-14 ES ES08850226.5T patent/ES2476257T3/es active Active
-
2010
- 2010-05-06 IL IL205611A patent/IL205611A0/en unknown
- 2010-05-12 ZA ZA2010/03363A patent/ZA201003363B/en unknown
- 2010-05-13 DO DO2010000143A patent/DOP2010000143A/es unknown
- 2010-06-09 CO CO10069276A patent/CO6280441A2/es active IP Right Grant
- 2010-06-14 EC EC2010010254A patent/ECSP10010254A/es unknown
- 2010-06-14 CR CR11499A patent/CR11499A/es not_active Application Discontinuation
-
2011
- 2011-02-25 HK HK11101918.4A patent/HK1146693A1/xx not_active IP Right Cessation
-
2012
- 2012-10-22 US US13/657,555 patent/US8951998B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31470A1 (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
DOP2019000218A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas | |
UY30527A1 (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
UY30391A1 (es) | Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c | |
CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
ECSP088258A (es) | Inhibidores de serina proteasas | |
CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
UY28423A1 (es) | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- | |
MX2010010276A (es) | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. | |
MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
HN2011000209A (es) | Compuestos macrociclicos de quinoxalina como inhibidores de la proteasa ns3 de vhc | |
MX2011012155A (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c. | |
MX2010006518A (es) | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. | |
MX2010008109A (es) | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). | |
MX2010008108A (es) | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. | |
ECSP088650A (es) | Compuestos de amido y su uso como productos farmaceuticos | |
UA109532C2 (xx) | Макроциклічні інгібітори серинових протеаз гепатиту с |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20171017 |